The use of lidocaine in spinal anaesthesia is associated with transient neurological syndrome (TNS). Bupivacaine has a lower incidence of TNS as an alternative but it may have a prolonged action. This study systematically reviews the literature about the recovery profile of patients undergoing spinal anaesthesia, using bupivacaine for arthroscopic knee surgery. We identified 17 eligible randomized clinical trials (RCTs) (1268 patients). All the articles in this review, except one, used hyperbaric bupivacaine. Five trials compared different doses of bupivacaine (range 3-15 mg). Large doses of bupivacaine (10 and 15 mg) were associated with delayed recovery, and supine positioning was associated with a high incidence of failure. With unilateral positioning, a dose as low as 4 -5 mg seems to be sufficient. Five trials comparing bupivacaine or levobupivacaine with ropivacaine showed no significant difference in the time to home discharge. When bupivacaine was combined with fentanyl in two trials, marginal delay in recovery was found [time to discharge (min); weighted mean difference (WMD) 14.1, 95% CI 11.9 -40.1] and increased nausea and pruritus but had reduced postoperative pain. Unilateral and bilateral spinal anaesthesia were assessed in two trials, and the latter group was associated with early recovery and discharge [time to discharge (min); WMD 241.6, 95% CI 263.6 to 219.6). The results of our systematic review suggest that 4-5 mg of hyperbaric bupivacaine can effectively produce spinal anaesthesia for knee arthroscopy with unilateral positioning. Ropivacaine or the addition of adjuvants did not improve the recovery time. There is a need for tighter RCTs with more consistent endpoints. 2009; 102: 307-15 
The use of lidocaine in spinal anaesthesia has declined over the years and has become virtually nonexistent because of the high incidence of transient neurological syndrome (TNS). The abandonment of lidocaine in spinal anaesthesia, however, has been a setback for ambulatory anaesthesia, where early recovery is vital. Bupivacaine, the most common alternative to lidocaine, has a low incidence of TNS (0-1%) 32 33 36 but delays home discharge in ambulatory surgical patients if used in the usual doses. strategies included: 'bupivacaine', 'spin$', 'an?esthesia', 'ambulatory', 'out?patient', 'day?case', 'surg$', 'knee', 'arthroscop$'. We also exploded the following index-word terms: 'ambulatory surgical procedures', 'anesthesia, spinal', 'bupivacaine', and 'arthroscopy'. We hand-searched reference lists from the already retrieved articles to identify further trials. In addition, contact was made with the principal authors and experts in the field to identify additional published or unpublished data relevant to the review.
Study selection criteria
Three reviewers (G.S.N., A.A., and J.L.) independently assessed titles, abstracts, or both of the hits retrieved from the electronic database and hand searches for possible inclusion according to the pre-defined selection criteria. Discrepancies were resolved by the fourth author (F.C.). Studies were eligible for inclusion if they were randomized clinical trials (RCTs) with parallel-group design, that evaluated the use of bupivacaine for spinal anaesthesia during elective knee arthroscopic surgery in ambulatory settings. Observational studies (e.g. non-randomized trials, case series) were not considered for review. There was no language restriction but all trials included in the review were published in English.
Data extraction
We extracted the following information about each study: method of randomization, number and characteristics of study participants, trial design, treatment regimens, time to onset of spinal block, duration of specific positioning after placing the block, incidence of unilateral and bilateral spinal block, time to recovery, time to voiding, time to home discharge, incidence of complications and failures. Data were extracted from each trial by two reviewers (G.S.N. and A.A.), checked for consistency and accuracy, and then entered into a computer database for analysis. The authors of included trials were contacted for the missing data.
Assessment of study methodological quality
Methodological quality was defined as the confidence that the design, conduct, and report restrict bias in the intervention comparison (Cochrane Handbook) as evaluated independently by the reviewers (G.S.N., A.A., and J.L.). Disagreements were resolved by the fourth author (F.C.). We assessed each study for the method of randomization, and of concealment of study intervention allocation, the degree of blinding, and the completeness of follow-up. Randomization method was considered adequate if it was generated by a table of random numbers, or computergenerated. Quasi-randomized trials (research design that does not ensure true randomization) were not included and assessed in this review. Allocation concealment was graded adequate if the allocation of patients is carried out by independent staffs who are not involved in the study, using methods such as serially numbered opaque-sealed envelopes, on-site locked computer, etc. Blinding was adequate if the patient, care givers, and outcome assessors are blinded to the treatment. Follow-up was adequate if the numbers and reasons for dropouts and withdrawals in all intervention groups are described or if it is specified that there were no dropouts or withdrawals.
Data analysis
Statistical methods of RevMan analyses (Review Manager, version 2.4, The Nordic Cochrane Centre, Copenhagen, Denmark) were used for analysing the data. In this review, pooling of the data was possible among the results of studies comparing bupivacaine with ropivacaine and studies evaluating the role of adjuvants and different positioning. Pooled treatment effects were estimated using both fixed-and random-effect methods. However, in the text, we have reported only the fixed-effect model, as the two analyses came into a similar conclusion in the sensitivity analyses. However, with regard to the different doses of bupivacaine, the available trials have reported the outcomes in variable formats. For example, time to discharge or voiding is reported as mean (SD) in some trials and as median with range or inter-quartiles in others. This factor along with the evident clinical heterogeneity (e.g. different design) among the trials led us not to proceed to meta-analysis in this group of studies. The results of these trials, however, were reported in the review for descriptive and qualitative analyses. For continuous variables, for example, time to voiding, we calculated the weighted mean difference (WMD) with corresponding 95% confidence intervals (CIs). No dichotomous data were pooled in this systematic review. The I 2 statistic was used to measure inconsistency among the study results.
, where Q is the x 2 statistic and df is its degrees of freedom (Cochrane Handbook). This describes the percentage of the variability in effect estimates that is attributable to heterogeneity rather than to sampling error (chance). A value .50% may be considered substantial heterogeneity. Subgroup analyses and assessment of publication bias (funnel plot) were not possible because of the limited number of studies used for pooling of the data. We analysed data with both fixed-and random-effect model for sensitivity analyses.
Results
The literature search performed in December 2007 identified 626 articles of potential relevance. The study selection process eliminated 437 articles by a review of the abstracts and titles. Another 117 articles were excluded after a review of their methodology and results sections. This process left us with 72 articles on spinal anaesthesia with bupivacaine for arthroscopic knee surgeries in ambulatory care (Fig. 1) . The study was designed to include only randomized controlled trials. After eliminating duplicate articles (studies that are published in more than one journal or cited more than once in the same database) and non-randomized trials, only 15 articles (a total of 1248 patients) 6 8 9 11 13 16 22-24 28 31 37 39 51 58 remained. The authors of the articles with insufficient data were contacted to get more information on the data. All of the trials are included in the review and are fully referenced.
The average age of the patients was 41 yr (range 18-83). The average sample size was 33 patients (range . All the articles in this review, except one, 13 used hyperbaric bupivacaine. The RCTs were then divided into four groups. The first group was trials comparing different doses of bupivacaine, 6 11 16 37 58 the second group those comparing the effects of adding adjuvants, 8 31 39 51 the third group those comparing bupivacaine with ropivacaine, 9 13 16 22 28 and the fourth group comparing different patient positions after administering spinal anaesthesia. 23 24 Methodological quality of the trials Eleven of the total 16 trials met all the factors of methodological quality and they have reported adequate methods for randomization, allocation, concealment, blinding, and completeness of follow-up. The remaining five trials 9 22 23 51 58 were associated with moderate risk of bias because they were not clear in the method of randomization, allocation, concealment, and blinding.
Trials comparing different doses of bupivacaine
There were five trials 6 11 16 37 58 comparing different doses of bupivacaine ranging from 3 to 15 mg. The trials include a total of 387 patients. Three trials had two comparison groups 16 37 58 and two trials had more than two groups 6 11 ( Table 1 ). Time to onset of block, time to voiding, home discharge, and failure rates were compared in the five trials. The definition used to describe the onset of block was heterogeneous between the trials. The criteria for home discharge used in the trials were based on standard criteria of stable cardiovascular and respiratory system, ability to void and walk with crunches, but were not uniform between trials. Failure was considered when general anaesthesia had to be given because of inadequate block. In some trials, values were reported as mean (SD), and in others as median (range). The authors of these trials were contacted for more relevant data, but the response rate was poor. Therefore, statistical pooling of the data was not feasible. Studies comparing different doses of bupivacaine can be divided into two groups on the basis of the positioning of the patient during spinal anaesthesia, 6 11 16 37 58 as position affects the distribution of the drug in the subarachnoid space and hence affecting recovery. Unilateral position 11 16 37 58 results in the concentration of the drug, on the one hand, and hence the need for reduced dose. In one study, 6 doses of bupivacaine 5 -15 mg were given, with patients in the supine position. The higher doses (10 and 15 mg) resulted in significant delay in time to voiding (.240 min) and time to home discharge (.260 min) without any significant changes in time to the onset of sensory block when compared with the 5 mg dose. However, the lower dose (5 mg) given in the supine position was associated with a high incidence of failure (.25%). On the other hand, three studies 11 16 58 (n¼327 patients) compared different doses of bupivacaine from 3 to 8 mg, as unilateral spinal, and had variable time to recovery. We showed that the studies using the same dose of medication reported variable time to discharge (Fig. 2) . On average, time to voiding ranged from 170 to 240 min and time to home discharge varied from 180 to 240 min. Valanne and colleagues 58 showed that 4 and 6 mg bupivacaine has a failure rate of 6.2% and 1.9%, respectivelystatistically not significant. No failure of anaesthesia was reported in the other three trials using doses of 3 -8 mg.
11 16 37 It was also shown that intermediate dose of bupivacaine (i.e. 6 or 7.5 mg) was associated with increased time to recovery when compared with lower doses. For example, in 90 patients, 16 bupivacaine 7.5 mg increased time to discharge by 40 min compared with 5 mg (P,0.05, Table 1 ). A similar pattern was reported in a Fig 1 Flow chart of screened, excluded, and analysed papers. †The total number of the trials is not the sum of studies for each comparison. There is one study 16 which includes two types of comparison.
Bupivacaine in ambulatory spinal anaesthesia comparison of bupivacaine 4 and 6 mg 58 (i.e. the delay in time to home discharge .20 min, P,0.05; Table 1 ). Trials also showed that the height of the maximum sensory block was similar among the different dosages. Time to onset of sensory block was slightly lower (i.e. 2 -3 min lower) after higher doses of bupivacaine; however, it was not clinically significant ( Table 1 ). The incidence of complications in the included studies is very low. There was no reported incidence of TNS in any of the included trials. The most common reported complication is post-dural puncture headache and its incidence is $1%
11 to 4% 58 (P.0.05) The incidences of other complications such as nausea, vomiting, and urinary retention are between 0% and 1%. Data regarding intraoperative complications were not reported.
To summarize, hyperbaric bupivacaine showed a significantly prolonged recovery with high doses (e.g. 10 or 15 mg). In the supine position, a lower dose (5 mg) has a higher incidence of failure (25%). In the unilateral position, however, doses of bupivacaine as low as 4 -5 mg can produce enough anaesthesia with no or very low incidence of failure. Increasing the dose of medication to 6 -7.5 mg may result in delayed recovery without any significant changes in failure rate.
Studies comparing the effect of adding adjuvants to bupivacaine
Four trials 8 31 39 51 (260 patients with mean age 39-42 yr) compared the effect of adding opioid adjuvants to bupivacaine for arthroscopic knee surgeries in the day-case setting (Table 2) . Fentanyl was added to bupivacaine in all four trials, and morphine was added to bupivacaine as a third group in one. 8 Fentanyl was used in a dose of 10-25 mg along with varying doses of bupivacaine. One study 8 
Table 1
Studies on different doses of bupivacaine used for spinal anaesthesia in knee arthroscopy. used a high dose of bupivacaine (12 mg) but the others used doses of 3-6 mg. 31 39 51 One trial was excluded from the statistical analysis because of insufficient data. 8 Pooling of data from three trials 8 31 39 showed no significant change in discharge time when fentanyl was added to bupivacaine for spinal anaesthesia (WMD 28.0, 95% CI 223.0 to 6.9, P¼0.20, Fig. 3 ).
All the trials reported an increased incidence of side effects when fentanyl was used as an adjuvant. The most notable side effect was the incidence of pruritis of 48-75% in the fentanyl group compared with 0-4% in the bupivacaine-alone group. In spite of this high incidence of pruritus in the opioid group, only 15-23% of the patients needed treatment. Other side effects such as hypotension (,1%) and urinary retention (,1%) were equally distributed between the groups. The addition of morphine resulted in longer recovery time than plain bupivacaine or plain bupivacaine plus fentanyl. 31 On the other hand, qualitative analysis showed that the use of intrathecal opioids was associated with reduced pain scores and decreased analgesic requirement in the postoperative period. Overall, using intrathecal opioids for knee arthroscopy in ambulatory anaesthesia results in a prolongation of discharge by 14 min (P¼0.21, Fig. 3 ) and a higher incidence of pruritus but has the benefit of reducing the postoperative pain scores.
Studies comparing bupivacaine with ropivacaine
There were five trials 9 13 16 22 28 that compared the different doses of bupivacaine or levobupivacaine with ropivacaine for spinal anaesthesia in outpatient knee arthroscopies. In two of the trials, 9 13 levobupivacaine was compared with ropivacaine; in two others, 22 28 racemic bupivacaine was compared with ropivacaine; and one studied all three drugs in three different groups. 16 Pooling of data was not possible, as there is a significant heterogeneity in the data and there is variation in the isomer of bupivacaine used in these trials.
Descriptive analysis of data showed that there was no significant difference between bupivacaine or levobupivacaine, and ropivacaine with regard to time to voiding, time to discharge, and side effects (Table 3) . However, in two trials, 12 22 there is a longer time to onset and shorter time to recovery from motor and sensory block with ropivacaine than with bupivacaine or levobupivacaine. But this did not change the time to home discharge. A trial 28 aimed at calculating the dose potency ratio of bupivacaine and ropivacaine concluded that bupivacaine was 1.5 times as potent as ropivacaine. Our search did not yield articles that compared bupivacaine and other local anaesthetics such as mepivacaine or chloroprocaine for knee arthroscopy. Overall, ropivacaine shows a similar profile to bupivacaine when used in knee arthroscopy in day-case setting.
Trials comparing unilateral and bilateral spinal anaesthesia
Two trials 23 24 of 170 patients compared the effect of unilateral and bilateral spinal anaesthetic ( 50 39 (14) Fentanyl (10) 169 (52) 50 35 (11) Fentanyl (25) NA NA Saline operating side lateral for 10 -15 min after the administration of the spinal anaesthetic. Bilateral spinal anaesthesia is defined as a patient positioned supine immediately after the administration of the spinal anaesthetic. The analysis of discharge time revealed that unilateral spinal anaesthesia was associated with an early recovery and discharge (Fig. 4) . Patients who had received unilateral spinal anaesthesia were ready for discharge to home, on an average, 42 min earlier than patients who received bilateral spinal anaesthesia. In patients in whom unilateral spinal anaesthesia was attempted, 55 -86% had pure unilateral sensory anaesthesia, and 75-95% had pure unilateral motor block. Unilateral spinal anaesthesia also resulted in a denser block (mean Bromage scale 14 score for motor block in bilateral patients was 0/1/2/3:0/2/0/45 compared with unilateral patients, 0/1/2/3:4/1/6/36) on the operating side. Unilateral spinal anaesthesia is also associated with a lower incidence of side effects such as hypotension (0 -6% vs 9 -28%, P,0.05). The incidence of bradycardia is 0 -8% in the unilateral group and 5 -10% in the bilateral group (P.0.05). There was no incidence of post-dural puncture headache and nausea. Eight per cent to 9% of patients in the unilateral group developed urinary retention compared with only 2 -5% patients in bilateral spinal anaesthesia, but this was not significant (P.0.05).
Discussion
Our results suggest that low doses of hyperbaric bupivacaine 4 -5 mg can effectively produce spinal anaesthesia with unilateral positioning in knee arthroscopy. Higher doses or bilateral positioning may result in delayed recovery or high rate of failure, respectively. Ropivacaine or the addition of adjuvants did not improve the recovery time.
In terms of technique, almost all studies used unilateral patient position after the administration of spinal anaesthesia. This might explain the high rate of failure (25%) in the 5 mg group in one study. 6 In the supine position with a bilateral spinal, the medication is distributed over a larger area and less becomes available to produce sensory nerve block at the site of surgery. Using a unilateral position, doses of bupivacaine as low as 4 -5 mg can be effective for knee arthroscopy.
11 16 37 The lower dose of 3 mg also showed no incidence of failure; however, it was used in only 20 patients in one study. 37 Increasing the dose to 6 or 7.5 mg did not make any significant change but delayed the recovery time. Among the unilateral spinal studies using a lower dose of 4 or 5 mg bupivacaine, there is varied time to recovery ranging from 170 to 240 min, translating to 1 h difference in time to home discharge. To draw a final conclusion on the optimal dose of bupivacaine, larger trials with head-to-head comparison between low doses of bupivacaine 4 -5 mg given in the unilateral position are required.
In comparison with the other outpatient surgery, motor paralysis is not required and a lower level of spinal anaesthesia is sufficient in knee arthroscopy. This might explain the low rate of failure with 4 -5 mg bupivacaine. However, similar failure rates of $5% 35 and 6% 24 38 are seen in other observational studies of knee arthroscopy patients, irrespective of the dose of bupivacaine used. Also, similar incidence of failure (5-10%) is seen in obstetric and general surgical patients 29 47 who received bupivacaine. Factors other than dose such as the technique of administration might be the cause of failure.
In this review, trials using intrathecal opioids in knee arthroscopy patients in day care anaesthesia showed a reduction in the postoperative pain score but caused higher side effects of opioids. The incidence of moderateto-severe pain in postoperative day-case patients ranges from 30% to 40% 50 and hence any method that reduces pain is beneficial. However, the benefit of good postoperative analgesia obtained with opioids has to be balanced against their side effects. Among all the side effects of intrathecal opioids, pruritus (50 -75%) was most common. This corroborates with a recent study 46 which reported a higher incidence of pruritus with knee arthroscopy than other surgical patients, and pruritus further increased with the use of bupivacaine rather than lignocaine. The increased pruritus can be a disadvantage in day care patients in whom anaesthetic management is tailored to reduce side effects. The incidence of other side effects such as nausea and vomiting, urinary retention, 30 and hypotension is low in the reviewed trials. Studies in mice, 1 and in obstetric 7 10 21 and orthopaedic 5 patients also showed that intrathecal opioids reduced the dose of local anaesthetic and improved the quality of anaesthesia. Other adjuvants that have been added to spinal anaesthesia such as clonidine 48 and neostigmine 48 prolonged recovery and may not be acceptable in day-case patients.
Qualitative analysis of data from the five trials comparing bupivacaine and ropivacaine 45 in knee arthroscopy patients did not reveal any difference in terms of time to home discharge. However, comparisons of bupivacaine and ropivacaine in knee arthroscopy patients 9 22 suggest a delayed onset and early recovery with ropivacaine. The shorter duration of the action also corroborates with trials in Caesarean section. 2 4 15 27 43 The shorter duration of action of ropivacaine can be explained by the lower potency of ropivacaine as shown in human volunteer studies 44 and studies of ropivacaine in epidural anaesthesia. 25 41 However, the early recovery in these trials did not translate into early discharge, and this could be attributed to other factors such as administrative factors that decided the time to home discharge.
Other local anaesthetics including mepivacaine, 54 57 chlorprocaine, 17 20 and prilocaine 52 56 have been used for spinal anaesthesia in ambulatory setting. These local anaesthetics are short-acting but have their own side effects. 42 59 The literature search for this review showed that there were no randomized controlled trials comparing bupivacaine with these short-acting agents for arthroscopic knee surgery.
This review shows that unilateral spinal anaesthesia is associated with a significantly early recovery and readiness for home discharge. Unilateral block allows a lower dose of local anaesthetic to be used by concentrating the drug on one side giving a denser block. The use of a smaller dose results in a reduced incidence of side effects such as bradycardia, hypotension, and urinary retention. 18 19 55 An important consideration while performing unilateral spinal anaesthesia is the extra time required for keeping the patient in the lateral position for the local anaesthetic to 'fix'. Overall, unilateral spinal anaesthesia offers early discharge with fewer side effects and can be utilized as a useful method in day-case knee arthroscopies.
The baricity of local anaesthetic agent is an important determinant of the outcome of spinal anaesthesia. In this review, the influence of different baricities on the results could not be evaluated because all used only hyperbaric bupivacaine. 40 It has been shown that both hyperbaric and plain bupivacaine can be suitable alternatives for adult outpatient knee arthroscopy but hyperbaric bupivacaine provides a more unilateral spinal block. 40 This is, however, one area for future research, as more studies comparing plain and hyperbaric bupivacaine in patients for outpatient knee arthroscopy are required to clarify which allows an early home discharge.
The results of this systematic review should be interpreted in the presence of the following limitations: the included RCTs are very diverse and heterogeneous with regard to the definition of the study outcomes, techniques, and their results. Each study used loss of sensation at different spinal levels to determine the onset of block. The method used to test for sensory loss also varied between 
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Fig 4
Meta-analysis of the discharge times comparing bupivacaine unilateral vs bilateral positioning for spinal anaesthesia using bupivacaine in knee arthroscopy. The horizontal line with box shows the respective odds ratio (95% CI) for individual studies and the dark diamond represents the pooled WMD.
studies. The recovery endpoints also varied between studies. Recovery of sensation at S1 was considered in few studies, whereas some studies used time to voiding as time to recovery. There is also variation in the way the data were presented in the different studies. Some reported in mean and SD and others mentioned median and range. In terms of technique, all but one used a unilateral patient position after the administration of spinal anaesthesia. Future studies require more consistent design and sample size. The dose of local anaesthetic needs to be standardized, patient positioning made more uniform, and concentration of the drug also made standard.
In conclusion, our review suggests that an appropriate low dose of bupivacaine for day-case knee arthroscopy is 4 -5 mg given in the unilateral position. Higher doses resulted in delayed recovery, and bilateral positioning caused a higher rate of failure. The best recovery profile occurs with unilateral positioning. Ropivacaine or the addition of adjuvants did not improve the recovery time of patients. The level of evidence for all the conclusions described here is 1a and the grade of recommendation is A. 3 To draw a definite clinical conclusion about the optimum dose of bupivacaine, future quality RCTs with consistent design and more sample size are required.
